News
TENX
1.750
-1.69%
-0.030
Weekly Report: what happened at TENX last week (0810-0814)?
Weekly Report · 6d ago
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law
Barchart · 08/16 16:38
TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)
Barchart · 08/14 09:53
Tenax Therapeutics Price Target Cut to $5.00/Share From $27.00 by Chardan Capital
Dow Jones · 08/11 16:12
Tenax Therapeutics Cut to Neutral From Buy by Chardan Capital
Dow Jones · 08/11 16:12
Tenax Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow Jones · 08/11 16:04
Tenax Therapeutics Price Target Cut to $4.00/Share From $35.00 by Canaccord Genuity
Dow Jones · 08/11 16:04
Chardan Capital Downgrades Tenax Therapeutics to Neutral, Lowers Price Target to $5
Benzinga · 08/11 16:02
Tenax Therapeutics downgraded to Neutral from Buy at Chardan
TipRanks · 08/11 15:40
Tenax Therapeutics Price Target Cut to $4.00/Share From $40.00 by Guggenheim
Dow Jones · 08/11 14:29
Tenax Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 08/11 14:29
Guggenheim Maintains Buy on Tenax Therapeutics, Lowers Price Target to $4
Benzinga · 08/11 14:19
Tenax Therapeutics Cut to In-Line From Outperform by Evercore ISI Group
Dow Jones · 08/11 12:48
Tenax Therapeutics Price Target Cut to $5.00/Share From $39.00 by Evercore ISI Group
Dow Jones · 08/11 12:48
Evercore ISI Group Downgrades Tenax Therapeutics to In-Line, Lowers Price Target to $5
Benzinga · 08/11 12:38
Tenax Therapeutics price target lowered to $4 from $35 at Canaccord
TipRanks · 08/11 11:00
Tenax Therapeutics price target lowered to $4 from $40 at Guggenheim
TipRanks · 08/11 10:51
Tenax Therapeutics price target lowered to $4 from $26 at Leerink
TipRanks · 08/11 10:15
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tenax Therapeutics (TENX) and Cogent Biosciences (COGT)
TipRanks · 08/10 22:30
Tenax Therapeutics Cut to Market Perform From Outperform by William Blair
Dow Jones · 08/10 20:39
More
Webull provides a variety of real-time TENX stock news. You can receive the latest news about Tenax Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TENX
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).